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Abstract
Restenosis after angioplasty occurs in 30–40% of the treated patients. To develop a strategy to deliver drugs to restenotic lesions, we
selected phages that bind to proliferating vascular smooth muscle cells (VSMC), from a random constraint 15-mer peptide phage display
library. Phages were selected for binding to cultured primary aortic VSMC (in vitro biopanning) and selected for binding to denudated carotid
arteries in mice (in vivo biopanning). In vitro biopanning did not result in a consensus sequence, but recurring FLGW and LASR amino acid
motifs were identified. In vivo biopanning resulted in two consensus peptides 5G6 (CNIWGVVLSWIGVFPEC) and 5E5
(CESLWGGLMWTIGLSDC). Surprisingly, these two sequences were recovered after both in vitro and in vivo biopanning, but
predominantly in vivo. Moreover, a strong recurring motif, IGR, was identified in the in vivo clones. The consensus phages 5G6 and 5E5
bind selectively to VSMC compared to other cell types. Furthermore, they bind preferentially to proliferating VSMC compared to VSMC that
were growth arrested, and are effectively internalized by their target cells. The specific binding capacities of 5G6 and 5E5 phages suggest that
these peptide sequences can be used for targeting of restenotic lesions, in which proliferating VSMC are the dominant cell type.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Restenosis is an inflammatory process similar to athero-
sclerosis, in which the migration and proliferation of vas-
cular smooth muscle cells (VSMC) plays an important role
[1]. These events are associated with a phenotypic change of
VSMC, characterized by modification in gene expression
[2]. Promising therapeutic effects in a rat model can be
accomplished by cytostatic drugs such as taxol [3], or
adenoviral gene therapy [4]. However, a major complication
of this approach is delivering sufficient amounts of these
therapeutics to the restenotic plaque, as systemic adminis-
tration of high doses of cytostatic drugs or adenovirus can
lead to cytotoxic effects [5].
Local delivery of therapeutics to prevent restenosis are
invasive and most of them limited to the moment of
angioplasty itself. To apply the drug of interest, a coated
or porous balloon [6,7] can be used during angioplasty.
Other local delivery systems involve catheter-based appli-
cation [8,9] or direct pericardial injection [10]. However, not
all of the diseased vessels will be readily available for local
injection. Systemic treatment, in which the delivery system
after intravenous administration will be able to specifically
target the restenotic plaque, could overcome these problems
and also enable to continue the treatment after angioplasty.
Systemic applications in restenosis require a ligand that
selectively targets the proliferating VSMC in the restenotic
plaque, thereby greatly enhancing its efficacy.
Antibodies specific for proliferating VSMC have been
shown useful in targeting atherosclerotic lesions in humans
and rabbits upon systemic injection. Moreover, modification
of the antibody with poly-L-lysin for additional negative
charge was necessary to reduce a non-specific uptake
[11,12]. Whereas atherosclerotic lesions in the rabbit are
only a few cell layers thick, the size of antibodies could
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cause a problem in penetration of restenotic plaques, which
are characterized by a dense extracellular matrix. Other
limitations to this approach may involve the high costs of
antibody production, toxicity and the immunogenicity of
their targets [13,14].
As an alternative for antibodies, peptides with high cell
binding capacity and specificity may be used. Synthetic
peptides with IC50 values within the micromolar range
[15,16] and even nanomolar range when binding to struc-
tural proteins like glycosaminoglycans and integrins [17–
19] have been reported. Furthermore, peptides are small
molecules that are easy to synthesize and are easily coupled
to the desired drug. Using a peptide phage display library,
large numbers of peptides can be screened for binding to the
target cells in vitro using biopanning [20–22]. Major
advantage of this approach is that no prior knowledge of
both ligand and receptor involved in the interaction is
required.
Phage display has also been shown to be very useful in
vivo, as phages are even stable enough to be injected
systemically and can readily be isolated from tissues without
loss of infectivity. Moreover, in vivo selection of phages has
resulted in peptides that are very effective and specific in
targeting the organs they were selected for upon systemic
injection [23–25]. For this reason, we selected peptides that
bind to mouse proliferating VSMC both in vitro in primary
cultured VSMC as well as in vivo in a denudated mouse
carotid artery using a random constraint 15-mer peptide
phage display library. The selected phages selectively bind
to VSMC compared to other cell types, with a preference for
proliferating VSMC.
2. Materials and methods
2.1. Cell culture
VSMC: aortas were isolated from male C57Bl6 mice,
washed with sterile phosphate buffered saline (PBS) and
digested in Hanks containing 2 mM L-glutamin, 0.3%
bovine serum albumin (BSA) and 1 mg/ml collagenase for
90 min at 37 jC. Resulting cells were pelleted and washed
with sterile PBS. The cells were plated onto 0.1% gelatin-
coated plates using DMEM (Gibco) + 10% newborn calf
serum (NCS). The cells were identified as VSMC by
positive and homogeneous immunocytochemical staining
for a-SM-actin and VCAM-1 (>90%), known VSMC
markers. Also, the cultured cells were positive in RT-PCR
for a-SM-actin, SM-22a, vimentin and osteopontin (Fig. 1).
The cultured cells were used at high passage numbers
(passage 13– 30) to ensure a proliferative, dedifferentiated
character. The morphology of the cells resembled the so-
called ‘cobblestone’-like phenotype of dedifferentiated
aortic SMC at confluency. To obtain the proliferating
phenotype, VSMC were seeded at low density the day
before use, whereas differentiated VSMC were allowed to
differentiate for 3 days in the presence of 250 U/ml heparin
or 1.5% NCS at high cell numbers.
2.2. Denudation of mouse carotid artery
Endothelial denudation of the arteria carotis communis
was induced by introducing a guidewire essentially as
described by De Geest et al. [28]. Female ApoE  / mice
were anesthetized with a mixture of 15 mg/ml ketamine,
5.7% Thalomonal, and 1% Hypnorm in PBS, 75–100 Al/10
g body weight, subcutaneously. Four ligatures were placed
around the arteria carotis communis, arteria carotis externa
and interna. Through a small incision distal from the branch
of the arteria carotis externa, a rough wire of 0.45 mm in
diameter (Cook) was introduced via arteria carotis externa
into the arteria communis. Denudation was induced by triple
withdrawal of the wire.
2.3. Biopanning procedures
2.3.1. Phage display library
A random 15-mer constrained peptide library was con-
structed in the pComb8 phagemid, and consists of a random
15 amino acid sequence, flanked by two cysteine residues
for a cyclic conformation. The library contains 1.8 108
peptide variants that are expressed at the N-terminus of the
major coat protein pVIII [26].
2.3.2. In vitro biopanning procedures
VSMC were plated into 60-mm dishes, at 7 105 cells/
dish, 20 h before selection. The cells were washed and
incubated in Hanks-complete (Hanks containing 2 mM L-
glutamin and 1% BSA) for 2 h at 37 jC. One hundred
library equivalents, 2 1010 cfu, in 1 ml Hanks-com-
plete + 100 AM chloroquine, were added and incubated at
37 jC for 1 h. After extensive washing with cold Hanks-
complete, all phages that associate with the VSMC but were
not internalized, were removed using either 0.2 M glycine/
HCl, pH 2.2 for 15 min on ice. Cells were lysed in 1 ml cold
NP-40 lysis buffer (50 mM Tris pH 7.5, 0.5 mM EDTA, 75
Fig. 1. RT-PCR analysis of VSMC cDNA with GAPDH, a-SM-actin,
SM22a, osteopontin and vimentin primers shows the presence of these
VSMC marker RNAs.
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mM NaCl, 0.5% NP-40, 1 mM PMSF, 20 Ag/ml aprotinin, 1
Ag/ml leupeptin) for 1 h on ice to release internalized
phages. The cell debris was scraped from the plate using a
cell scraper, and vortexed briefly. The selected phages were
amplified and titered using XL1-Blue E. coli bacteria and
VCS-M13 helper phage (Stratagene) and subsequently
sequenced as described [26,27].
2.3.3. In vivo selection procedure
Phages (1010 cfu) that were selected in vitro for overall
binding to VSMC during three rounds were injected in the
tail vein of denudated mice, 7 days after denudation. After 2
h, the mice were killed by an overdose of anesthesia and
perfused with Krebs–Ringer solution for 10 min. The
treated arteries were removed and dissected mechanically
first, followed by enzymatic digestion of the arteries in
Hanks + 2 mM L-glutamin + 0.3% BSA and 1 mg/ml colla-
genase, 1 mg/ml trypsin inhibitor and 0.47 U/ml elastase I
for 1 h at 37 jC. The reaction was terminated by adding 1
mM PMSF. The detached cells were collected by centrifu-
gation, dissolved in NP-40 lysis buffer and lysed at 4 jC for
1 h to collect phages.
2.4. Phage binding assay
Cells were plated into 96-well plates (1104 c/w) the
day before use. The cells were washed and incubated in
Hanks-complete at 37 jC for 2 h. Phages were added and
incubated with the cells for 2 h at 37 jC. Non-bound phages
were washed away extensively with Hanks-complete. The
cells and phages were fixed using ice-cold methanol, 10 min
at  20 jC. After fixation, the cells were washed with PBSS
(PBS + 0.1% saponin) + 5% milk and incubated with bio-
tinylated polyclonal anti-M13 serum (5 Prime! 3 Prime).
After this incubation, the cells were washed and incubated
with PO-labeled streptavidin (Amersham Life Science).
Peroxidase activity was detected with TMB (0.3 mg/
ml + 0.03% H2O2). The reaction was terminated with 1 M
H2SO4 and measured at 450 nm.
3. Results
3.1. In vitro selection
For biopanning, we used a random 15-mer constraint
peptide library in combination with proliferating cultured
aortic VSMC. Phages were added to a monolayer of
dedifferentiated, proliferating VSMC. After 1 h incubation,
non-binding phages were washed away. Phages bound to
the outside of the VSMC were removed by an acid wash.
Subsequently, cells were lysed to release internalized
phages. Collected phages were amplified and used for four
subsequent rounds of biopanning. Sequence analysis of a
total of 45 randomly picked clones from two separate
selections revealed no evident consensus sequence. How-
ever, some recurring motifs, mainly FLGWand LASR, were
identified (Table 1). Next, 96 clones of two separate
selections were picked and grown individually in a 96-well
plate. The clones were tested for binding to VSMC in a
phage binding assay and clearly show a high binding
capacity for VSMC compared to binding of an unselected
phage population and wild-type phages (Fig. 2).
3.2. In vivo selections
After five rounds of biopanning, still a wide variation in
sequences was detected. To find a consensus, phages were
subjected to in vivo selection upon injection in denudated
mice. For this purpose, endothelial cells aligning the carotid
arteries of ApoE / mice were removed using a rough
guidewire [28], leaving the VSMC exposed (Fig. 3). First,
Table 1
Motif analysis of resulting clones. Homologies between amino acid residues are shaded
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we determined at what day after denudation most VSMC
were exposed and proliferating. To ensure the formation of a
plaque, a wire with a diameter of 0.45 mm was used. This
treatment caused a significant loss of cells at the luminal
surface. It took about 5 days for the cells to recover, as
shown by HE staining. The amount of proliferation was
determined by BrdU-staining, showing that proliferation
was maximal at day 7 after denudation (not shown). Before
in vivo selections, phages were selected by three rounds of
biopanning on cultured VSMC, as described. In this case,
non-internalized phages were not removed, to ensure the
largest possible variation within this pre-selection. After
three rounds of in vitro biopanning, phages were injected
into the tail vein of denudated mice, 7 days after treatment,
and allowed to circulate for 2 h. After total body perfusion,
the carotid artery was removed and binding phages were
collected. After three rounds of additional in vivo biopan-
ning, 84 clones were picked and grown individually in 96-
well plates and tested for binding to VSMC in a phage
binding assay (Fig. 2).
Fourteen phages with highest binding capacity were
sequenced. This time, a consensus peptide sequence,
CNIWGVVLSWIGVFPEC, was present which represented
75% of the binding population. Surprisingly, the consensus
sequence was identical to phage 5G6, which was also
selected after biopanning in vitro. Another phage, 5E5
(CESLWGGLMWTIGLSDC), which was recovered after
binding to denudated carotid arteries, was also recovered
after in vitro biopanning on VSMC. This sequence occurred
only once in both selections (Table 2). Also, a clear motif,
IGR, was present in all of the in vivo selected peptides
(Table 1).
3.3. Specificity of selected phages for VSMC
To test the specificity of the selected phages to target
restenotic VSMC, they were tested for binding to other cell
types that will be encountered upon intravenous injection.
For this reason, VSMC, murine fibroblasts (3T3), endothe-
lial cells (H5V), murine monocytes and macrophages
(RAW) and liver cells (AT3) were cultured in 96-well plates
and the binding of phages to each cell type was determined.
The background uptake of unselected phages and wild-type
phage by RAW cells was relatively high, most likely due to
phagocytosis. Although the binding to 3T3 cells was gen-
erally lower than the binding to VSMC, this difference was
Table 2
Occurrence of peptide sequences. Binding to VSMC was determined using
phage binding assay
Clone Amino acid sequence Occurrence Binding
in vitro in vivo VSMC
5G6 CNIWGVVLSWIGVFPEC 1/45 10/14 ++ + +
5E5 CESLWGGLMWTIGLSDC 1/45 1/14 ++ + +
2G3 CSASFFSWLFGWELAC 1/45 0/14 ++ + +
Fig. 2. Binding of randomly picked phage clones to proliferating VSMC
after different selection procedures. The binding of wild-type (n) and
unselected phages (.) to proliferating VSMC were compared to phages
that were selected for internalization by proliferating VSMC in different
selection procedures. Clones were picked at random after five rounds of in
vitro biopanning (5, n= 96) and after three selection rounds in vitro
without removal of non-internalized phages, followed by three selection
rounds in vivo (o, n= 84). Binding was measured using a phage binding
assay. Each point represents the average binding of one clone in two
separate assays. Median values are indicated (black lines).
Fig. 3. Carotid artery of an ApoE /  mouse at day 7 after denudation.
Vascular smooth muscle cells were stained using an antibody against a-
smooth muscle actin (clone 1A4), a marker for vascular smooth muscle
cells (brown staining). Vascular smooth muscle cells are exposed at the
lumenal site, surrounded by excreted extracellular matrix (unstained).
Magnification  400.
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not significant. This can be explained by the fact that the
phenotype of proliferating VSMC becomes more fibroblast-
like during culturing, due to dedifferentiation. The consen-
sus phage 5G6 shows significant specific binding to VSMC,
compared to wild-type and unselected phages, as well as the
other phage that was selected both in vitro and in vivo, 5E5.
Another in vitro selected clone, 2G3, chosen for its high
binding capacity, binds with significant specificity to VSMC
as well (Fig. 4).
3.4. Specificity of selected phages for proliferating VSMC
Restenotic VSMC differ from normal VSMC. Restenotic
VSMC are VSMC that have dedifferentiated into a more
fibroblast-like stadium. They no longer contract, but are able
to migrate and proliferate, and to synthesize large amounts
of extracellular matrix, which leads to occlusion of the
arterial lumen. To be successful in targeting restenotic
lesions, selected phages must be able to bind to VSMC
with a restenotic phenotype. This means that they have to be
specific, mainly, for proliferating VSMC with a dediffer-
entiated phenotype.
Starvation at low serum is a common method to inhibit
cell growth and synchronize cells. More specific is inhib-
ition by heparin, which inhibits the growth of VSMC
specifically [29]. We tested both methods. At indicated time
points, cells were detached using trypsin and counted. As
suspected, low serum conditions (1.5% NCS) were very
sufficient in inhibiting the growth of VSMC, but VSMC
cells did not survive serum-free conditions in the presence
of 1% BSA. Significant inhibition of growth was also
obtained at heparin concentrations as low as 5 U/ml. Total
inhibition was accomplished at concentrations between 50
and 500 U/ml (Fig. 5A and B), while viability was unaf-
fected.
The amount of differentiation was determined by West-
ern blotting and staining for a-SM-actin, a differentiation
marker for VSMC. a-SM-actin expression was induced 3
days after the addition of 50–500 U/ml heparin, whereas
without heparin, only a minor a-SM-actin expression was
obtained only after 6 days, but never reached the same
levels of cells induced with heparin (Fig. 5C).
Both heparin-inhibited and serum-starved VSMC were
compared to proliferating VSMC for binding of the selected
Fig. 4. Binding of selected clones to different cell types. Cells were seeded at equal amounts per well and uptake of phages was measured after 2 h of incubation
using a phage binding assay. (A–C) Binding of selected phages to different cell types: 5G6, 5E5 and 2G3, respectively (black bars). Hatched bars: library
(unselected phage pool), white bars: wild-type (WT) phage (VCS-M13). 3T3: murine fibroblasts, H5V: murine endothelial cells, AT3 murine hepatoma cells,
RAW: murine monocytes macrophages. Each bar represents the meanF S.E.M. from three independent experiments. * p< 0.05, ** p< 0.01 and *** p< 0.001
obtained by ANOVA.
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clones and phage binding was assayed on confluent mono-
layers. To correct for possible differences in cell numbers
that will occur after several days of culturing, protein levels
were also determined. Subsequently, phage binding was
expressed as binding per amount of protein. The results
are shown in Fig. 5. All clones except 2G3 bound with
significant preference to proliferating VSMC compared to
heparin-inhibited VSMC. Similar results were obtained with
serum-starved VSMC, though the differences in binding
between proliferating and heparin-inhibited cells are less
apparent. Differences in binding of phages to heparin-
inhibited or serum-starved VSMC are difficult to explain
or to compare, because heparin is a multifunctional protein,
which is also able to trigger many other cell functions and
pathways.
3.5. Uptake of selected phages by VSMC
Binding of the selected phages to VSMC was visualized
by growing VSMC on glass coverslips, incubation with
phages and staining with biotinylated anti-M13 serum and
FITC-labeled streptavidin. Most phages show a granular,
lysosomal staining, whereas the consensus sequence 5G6
seems to be more concentrated around the nucleus. None of
the selected phages binds to heparin-inhibited VSMC (Fig.
6).
To examine whether phages do not just bind to the
surface of VSMC, but are also internalized by these cells,
we examined the uptake of phages after the addition of some
inhibitors of cellular uptake. Sucrose causes osmotic imbal-
ance, resulting in disturbance of clathrin-coated pit forma-
Fig. 5. Binding of selected phages to proliferating and non-proliferating VSMC. (A) Growth of VSMC at different serum levels, (B) growth of VSMC after the
addition of heparin, (C) western blot of VSMC (8 Ag protein/lane), stained for a-SM-actin, (D) binding of selected phages to proliferating VSMC (grey bars)
and low-serum proliferation inhibited VSMC (white bars), (E) binding of selected phages to proliferating VSMC (grey bars) and heparin-proliferation inhibited
VSMC (white bars). Binding was measured by a phage binding assay. Subsequently, phage binding was corrected for cell amounts by expressing binding per
amount of protein produced per well. Bars represent averageF S.D. (duplicates). * p< 0.05 and ** p< 0.01, obtained by Student’s t-test.
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Fig. 6. Immunolocalization of selected phages on VSMC. VSMC were plated onto glass cover slips and incubated with phages. Phages were stained using
biotinylated anti-M13 antibody and streptavidin-FITC (Amersham). Proliferating (A–C) and heparin growth inhibited VSMC (D,E) incubated with 5G6
phages (A,D), 2G3 phages (B) and wild-type phages (C,E) respectively. Magnification  200.
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tion and subsequently receptor-mediated uptake. Colchicin
is an inhibitor of microtubili-dependent transport, whereas
cytochalasin D is an inhibitor of actin-dependent transport.
Chloroquine inhibits the lysosomal pathway by lowering the
pH within the lysosomes. The results are shown in Fig. 7.
All three phages were inhibited in uptake by three or more
of the tested inhibitors, indicating that the phages are not
just binding to the surface of VSMC, but are readily taken
up.
4. Discussion
Intimal lesion formation after angioplasty is character-
ized by the hyperplasia of VMSC. Previously it has been
demonstrated that inhibition of proliferation and migration
of this cell type by cytostatic drugs or adenoviral therapy
can lead to diminished lesion formation [3,4]. However,
there is still a need for an effective delivery system that can
accomplish local delivery of drugs after systemic adminis-
tration. For restenosis, a ligand that targets proliferating
VSMC may greatly enhance the efficacy of drugs that
inhibit proliferation of VSMC.
In this study, we isolated phages from a random, 15-mer
constraint peptide phage display library that bind to pro-
liferating VSMC. We used both in vitro and in vivo
selection methods. In vitro biopanning did not result in a
real consensus sequence. However, a recurring motif could
be identified, like FLGW and LASR. After subsequent in
vivo selection in mice, two consensus phages, 5E5 and 5G6
(Table 2), could be identified. These sequences were
selected both in vitro and in vivo, but predominantly in
vivo. Also, a clear recurring motif, IGR, could be detected
in all sequenced clones (Table 1). Interestingly, consensus
motifs between phages selected via biopanning on living
cells or upon injection in vivo, often appear to be three or
four amino acid sequences [23,25,30,31]. In many phage
display studies involving selection of peptides on living
cells, like in vivo selection for skeletal muscle-binding
peptides [24] or in vitro selection on primary airway
epithelial cells [32], no consensus motif between the
selected phages can be detected at all. The identification
of a consensus motif is limited by the variation within the
library, as well as the length of the peptides encoded by the
library (15 amino acids), as not all possible combinations
will be present. The longer the encoded peptides, the less
possibilities will be present due to limited variation possi-
bilities of bacterial libraries. Therefore, libraries encoding
short peptides, for example, 6-mer libraries are more likely
to give rise to consensus motifs between selected peptides
Fig. 7. Inhibition of phage uptake by VSMC by different inhibitors. Inhibition of phage uptake by 0.2 M sucrose (A), 10 AM cytochalasin D (B), 10 AM
colchicin (C), 100 AM and 100 AM chloroquine (D). Phage binding was measured using phage binding assay. Bars represent averageF S.D. (duplicates).
* p< 0.05 and ** p< 0.01, obtained by Student’s t-test.
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than 12- to 20-mer libraries. Selection of phages on intact
cells as compared to selection using a defined protein adds
another important factor that reduces the chance of finding
consensus sequences, since peptides selected for a certain
cell type will bind to several targets, thereby scattering the
number of possible motifs even more. This scattering seems
to be dependent on the cell type or organ used for targeting.
Clearly, the expression of proteins with high ligand binding
capacities such as adhesion molecules or other cell-binding
proteins plays an important role, as well as their expression
levels on the cell type of interest. In vivo selection is even
more complicated, as this selection method is also highly
dependent on the vascularization of the target organ [24,33].
This way, it is more likely to end up with a consensus
sequence rather than a consensus motif. To find all possible
or improved motifs for cell binding, random mutation of the
consensus sequence has proven to be [20].
Analysis of amino acid composition of the selected
phages reveals that all selected sequences are relatively
apolar, with few positively charged amino acids. Blast
analysis showed no exact matches. However, significant
homologies (70% or more positive) between most of the
VSMC-selected phages and several protein groups could be
distinguished. A large group of VSMC selected phages
shares significant homologies with viral proteins and signal-
ing proteins, indicating that the selected phages might be
able to incorporate into the cellular membrane and enter the
target cell likewise. Also, homologies with ion transport
channels and G-protein-coupled receptors were listed, pro-
teins known for their large trans-membrane domains.
Another important group of phages shows high homology
with structural proteins like gelsolin and integrins, proteins
known to play an important role in VSMC and plaque
formation in restenosis. For example, one of the phages that
were selected both in vitro and in vivo, 5E5, matches a 10-
amino-acid-region within the extracellular part of integrin
a5 of three different species (mouse, human and bovine).
Together with the integrin h1 subunit, this integrin is known
as the fibronectin receptor, also called VLA-5 or CD49e.
Interestingly, nine of the phages we selected, including the
consensus 5G6 phage, share three amino acid homologies
with a peptide specific for an organ that merely consists of
SMC, the uterus-specific peptide, GLSGGRS [25].
The consensus phages 5G6 and 5E5 bound with a high
selectivity to VSMC compared to endothelial cells and liver
cells. Binding to fibroblasts, a cell type that shares high
homology with proliferating VSMC, was also lowered
compared to VSMC binding. However, a non-specific
uptake by macrophages was not abolished. Furthermore,
all selected phages tested bind preferentially to proliferating
VSMC compared to VSMC allowed to differentiate by
serum starvation or heparin. The results indicate that the
phages we selected, not only are specific for VSMCs, but
also for a specific physiological state of these cells. This
specific phenotype of VSMC is generally believed to play
an important role in the pathogenesis of restenosis [1]. Also,
our studies with inhibitors of cellular uptake showed that all
selected phages were effectively internalized by the target
cells.
Though using cultured cells for biopanning is more
easy and consistent, it is well known that the in vitro
situation can be quite different from the in vivo situation.
Therefore, we decided to select in vivo for restenotic
VSMC targeting peptides as well, using an established
mouse denudation model [28], in which the endothelial
cells were removed using a rough guidewire, to expose
the VSMC. In vivo phage display has proven to be very
effective in selecting phages with high organ specificity
upon systemic injection. However, these studies are based
on the fact that molecular heterogeneity of the vascular
endothelium can serve as addresses for each organ.
Endothelial cells are specialized in homing of blood cells
and humoral factors to the vascular wall. For this
purpose, they express a high number adhesion molecules
like selectins, ICAM, VCAM-1 as well as several types
of differentially expressed proteoglycans and integrins
[33,34]. In our case, selection occurred at the site of
early-phase restenosis, with lesions predominantly com-
posed of proliferating and migrating VSMC. To our
knowledge, there are no unique surface markers
expressed uniquely on VSMC, specialized in uptake of
blood-derived factors, which may make them more diffi-
cult to target.
Previously, we have shown that chemical modification of
wild-type M13 phages can alter plasma half-life and bio-
distribution of phages upon systemic injection. Conjugation
of phages with galactose and succinic anhydride resulted in
a significantly reduced plasma half-life, due to rapid and
specific uptake by the liver and spleen [35]. For in vivo
phage display, this implies that phages within a library
expressing ligands that cause rapid internalization, might
not reach their target at all. This will inevitably result in a
phage population that binds to the endothelium predomi-
nantly. This is illustrated by the fact that all previous in vivo
selections [23,25] and even an ex vivo study in denudated
rat carotid artery [36] using a naive phage library, resulted in
phages that preferentially bind to endothelial cells. Only the
group of Samoylova and Smith [24], who used cultures of
primary skeletal muscle cells to pre-select their phage
library, was able to recover peptides that target skeletal
muscle upon systemic injection. Also, previous attempts by
our group to select phages that bind to cells within vascular
lesions upon systemic injection in mice, using a naive phage
library, failed (unpublished results). To avoid that most
phages during in vivo selection would be cleared by
adherence to endothelial cells before reaching the site of
interest, we preselected them on primary cultures of VSMC,
enhancing the number of copies per phage for VSMC
targets. Furthermore, we chose to select for a longer time
period than previous studies, which are merely based on 4-
to 15-min systemic exposure, to avoid phage internalization.
We allowed the phages to circulate for 2 h, to be able to
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recover phages internalized by VSMC. To our knowledge,
this is the first study in which selection of phage binding to
VSMC over endothelial cell binding is established.
To investigate the in vivo targeting capacity of the
selected phages, each clone was re-infused into the
described restenotic mouse model. We observed accumula-
tion of phages in organs that are predominantly responsible
for the uptake of control phages (i.e. wild-type phages),
such as liver and spleen (unpublished observation). This
may be a result of the fact that only a limited number of the
coat protein VIII expressed by the phage carry the recombi-
nant peptide. We think that using the isolated peptide in our
future in vivo research will resolve this problem.
In conclusion, these results show that the selected peptide
sequences can be used for targeting to sites that are rich in
proliferating VSMC, like restenotic lesions. When coupled
to a drug, it may cause an enhanced and more efficient
uptake of the drug into lesions and into the target cells when
administrated systemically. The other way round, identifi-
cation of the receptor to which the selected peptides bind to,
might also result in the discovery of a VSMC-specific
receptor. Until now, no cell surface receptor specific for
VSMC is identified yet. Both the peptide and the receptor
can be used for drug or gene targeting, as well as imaging
studies.
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